Bryan Gilburg - China

“The TFDA will now require license holders submit installation records on an annual basis through their online portal.”

Bryan Gilburg

Managing Director, Asia Actual

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sources and Links

Sign Up For Our Newsletter to Stay Informed

Sign Up

TFDA Implements New Annual Reporting Requirements in Thailand

Published on: April 8th, 2022

Updated on: May 6th, 2022

On June 1, 2022, the Thai FDA released Gazette 138, Section 118 requiring license holders submit annual reports by March 31st of every year covering installations of products under the licenses they hold. Originally, all license holders were supposed to upload the reports by the end of March but due to issues with the e-portal, the TFDA is requesting hard copies as soon as possible and online submissions completed by September 30, 2022. The reports must include the date of sale/installation, name of the product, license number, manufacturing information, customer information, quantity, and value of purchase.

According to the new regulations, products registered under new rules (apply to applications submitted after February 15, 2021) that were imported/sold in the previous year must be reported to the TFDA by March 31, 2022. License holders could be prosecuted and fined for not submitting reports in time. Manufacturers can determine if their product is registered under the old or new rules by the format of their registration number. If it’s 65-2-2-2-0002736, then the product was registered under the new rules whereas if the license number has a 3 letter country abbreviation followed by 8 numbers (i.e. FRA 7311311) was registered under the old rules.

The original post can be found here and a Google translated version can be found here.

Additional Notes

The TFDA has not ruled out that there will be exceptions to this rule and will entertain questions from manufacturers on whether their products need to be reported in this format. For example, there may be some medical devices like software that do not collect installation records of every customer and may not be able to be able to feasibly report this information.

Regarding the values the TFDA will expect to see, the Import Value is the Import Entry Declaration (THB) while the Value of Sale can include all amounts except for VAT.

For more information on registering your medical device in Thailand, please see our page on the topic here.

Come Grow with Us

Contact Asia Actual if you’d like to learn how this regulation might affect your products in Thailand.

Asia Actual is a regulatory consulting company specializing in helping manufacturers grow their sales through independent license holding, direct fulfillment, and a variety of sales channel support services.

Blog Posts

China’s NMPA Updates Medical Device Classification Catalogue

China’s National Medical Products Administration (NMPA) maintains a list of all medical device categories called the Medical Device Classification Catalogue. NMPA published a notice on August 17, 2023, that they had released amendments to the Medical Device Classification Catalogue. It’s important for manufacturers to understand these changes as they can significantly impact the cost and time to register medical devices.

Thai FDA Drafting New Guidance for SaMD and AI Device Registration

Thai FDA is drafting new guidelines for AI Regulation. The novel characteristics of artificial intelligence (AI) software cause issues with the medical device registration process in most countries. The Thai Food and Drug Administration (Thai FDA) is working to address this important issue, most recently by hosting a meeting with interested parties on July, 2023, which Asia Actual Thailand employees were invited to attend.

China NMPA Adds 47 Products to Clinical Trial Exemption List

China’s National Medical Products Administration (NMPA) updated its clinical trial exemption list, adding 47 products. The NMPA updates this list every two to three years, with the last amendment in 2021. This brings the total number of clinical trial exempted product categories in China to 1,025.